Immune checkpoint inhibitor-induced inflammatory arthritis. [Review]

Fisher, BA.; Allard, A.; Dubey, S.; Mankia, K.; Pratt, AG.; Pallan, L.

Immune checkpoint inhibitor-induced inflammatory arthritis. [Review]

All Authors

Fisher, BA.

Allard, A.

Dubey, S.

Mankia, K.

Pratt, AG.

Pallan, L.

LTHT Author

Mankia, Kulveer

LTHT Department

NIHR Leeds Biomedical Research Centre
Rheumatology

Publication Date

2025

Item Type

Journal Article
Review

Abstract

Immune checkpoint inhibitors (ICI) used for the treatment of malignancy are associated with immune-related adverse events, which include inflammatory arthritis. ICI-induced inflammatory arthritis (ICI-IA) is a new clinical entity that may lead to functional impairment and may be persistent even after ICI cessation. We discuss the clinical features, investigation and differential diagnosis. Management needs to consider the safety of immunosuppression in the context of the underlying cancer, and current practice will be further informed by ongoing clinical trials.